Shanghai OPM Biosciences Third Quarter 2024 Earnings: EPS: CN¥0.028 (vs CN¥0.048 in 3Q 2023)

Simply Wall St

November 01, 2024

Shanghai OPM Biosciences (SHSE:688293) Third Quarter 2024 Results

Key Financial Results

Revenue: CN¥72.2m (up 43% from 3Q 2023).
Net income: CN¥3.10m (down 42% from 3Q 2023).
Profit margin: 4.3% (down from 11% in 3Q 2023). The decrease in margin was driven by higher expenses.
EPS: CN¥0.028 (down from CN¥0.048 in 3Q 2023).

earnings-and-revenue-growth — SHSE:688293 Earnings and Revenue Growth November 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai OPM Biosciences Earnings Insights

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 16% from a week ago.

Risk Analysis

Be aware that Shanghai OPM Biosciences is showing 3 warning signs in our investment analysis and 1 of those doesn't sit too well with us...

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.